menu
    • menu
    [{"orgOrder":0,"company":"Curi Bio","sponsor":"Dream CIS","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Protein","year":"2024","type":"Collaboration","leadProduct":"Clostridium Botulinum Toxin Type A","moa":"Undisclosed","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Curi Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Curi Bio \/ Curi Bio","highestDevelopmentStatusID":"15","companyTruncated":"Curi Bio \/ Curi Bio"},{"orgOrder":0,"company":"Curi Bio","sponsor":"Dana Solutions","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Acquisition","leadProduct":"Human Ipsc-Derived Cardiomyocytes","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Curi Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Curi Bio \/ Curi Bio","highestDevelopmentStatusID":"2","companyTruncated":"Curi Bio \/ Curi Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Curi Bio

    Menu

    Curi Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Curi Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Curi Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clostridium Botulinum Toxin Type A

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Recipient : Dream CIS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Curi Bio, Genetox, DreamCIS Sign MOU for Neuromuscular Junction Model

                            Details : DreamCIS will support the development of Genetox’s Botaone (clostridium botulinum toxin Type A) for treating glabellar and lateral canthal wrinkles using Curi Bio's neuromuscular junction model.

                            Product Name : Botaone

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            February 22, 2024

                            Lead Product(s) : Clostridium Botulinum Toxin Type A

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Recipient : Dream CIS

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Curi Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Curi Bio

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Ipsc-Derived Cardiomyocytes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Recipient : Dana Solutions

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Curi Bio Acquires Dana Solutions

                            Details : Through the acquisition, Curi will gain access to Dana’s AI/ML-based platforms including PhenoLearn™, a deep learning platform for modeling cell and tissue phenotypes; Pulse™, an automated platform for contractility analysis of beating cardiomyocyt...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            July 23, 2020

                            Lead Product(s) : Human Ipsc-Derived Cardiomyocytes

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Recipient : Dana Solutions

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth